Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
 Accreditation of IHMA Europe, Enhancing Support for Clinical Trials in Anti-Infective Drug Development and Global Surveillance Studies - EconoTimes)
SCHAUMBURG, Ill., March 06, 2018 -- On 14th October 2017 IHMA Europe Sàrl, located in Monthey, Valais, Switzerland, was awarded accreditation by the College of American Pathologists (CAP). With this important development both IHMA facilities, located in the US and Europe, are now CAP accredited. These accreditations further advance IHMA’s global commitment to the highest quality of central laboratory clinical microbiology services that are essential for providing timely and accurate results in support of anti-infective clinical trials and global surveillance studies on a worldwide basis.
IHMA Europe's Chief Executive Officer, Dr Stephen Hawser said, “CAP accreditation is a truly positive acknowledgement of the high quality of services IHMA Europe provides to the pharmaceutical and biotechnology industries to support antimicrobial development".
Jack Johnson, President and CEO of IHMA said, “It has been our desire to globalize the two laboratories to ensure our pharmaceutical and biotechnology clients, that all services provided by IHMA and IHMA Europe are exactly the same and meet the highest standards and quality found in our industry. The CAP accreditation provides that platform.”
About IHMA, Inc. and IHMA Europe Sàrl
IHMA is based in Schaumburg, IL USA and Monthey, Switzerland and has been a premier provider of antimicrobial drug development services over the past 25 years. Our laboratory facilities in both the US and Europe partner with clients around the world in the biotechnology, pharmaceutical, and diagnostic industries. IHMA is a leading, independent laboratory specializing in surveillance studies and clinical trials, key milestones along the continuum from drug development to commercialization. IHMA utilizes state of the art technology, leading to first-class testing and data as well as sound economic frameworks. IHMA’s services can be customized to best align with its clients’ unique testing needs. This ensures successful drug development, commercialization, and post-marketing pathways.
For more information, visit the IHMA website at: www.ihma.com
CONTACT INFORMATION
Igael Hamburg
Marketing Director
[email protected]
